BIOGRAPHIES OF SPEAKERS AND SESSION CHAIRS
Prof. Peter Maxwell
Queens University, Belfast, U.K
Peter Maxwell is a cons...
BIOGRAPHIES OF SPEAKERS AND SESSION CHAIRS
Dr. Lise Tarnow
Steno Diabetes Centre, Gentofte, Denmark
Dr. Lise Tarnow g...
BIOGRAPHIES OF SPEAKERS AND SESSION CHAIRS
UCD, his research group is focussed on applying molecular based strategies to
...
BIOGRAPHIES OF SPEAKERS AND SESSION CHAIRS
behaviour of epithelial cells. For the last 10 years he has contributed to the...
BIOGRAPHIES OF SPEAKERS AND SESSION CHAIRS
Dr. Roel Goldschmeding
University Medical Centre Utrecht, The Netherlands
...
BIOGRAPHIES OF SPEAKERS AND SESSION CHAIRS
Dr. Susan Quaggin
Samuel Lunenfeld Research Institute, Toronto, Canada
Sus...
BIOGRAPHIES OF SPEAKERS AND SESSION CHAIRS
Dr. Ruth Gimeno
Cardiovascular and Metabolic Diseases, Wyeth Research
Cambrid...
BIOGRAPHIES OF SPEAKERS AND SESSION CHAIRS
Foundation of Australia, Diabetes Australia and Kidney Health Australia. In 19...
BIOGRAPHIES OF SPEAKERS AND SESSION CHAIRS
Standardise Proteomics Methods in Kidney Research and European Kidney Health
I...
BIOGRAPHIES OF SPEAKERS AND SESSION CHAIRS
Hypertension Society and the Jan Brod Award, Czech Society of Hypertension. He...
BIOGRAPHIES OF SPEAKERS AND SESSION CHAIRS
/
Kumar Sharma
University of California, San Diego, California, USA
Kumar S...
BIOGRAPHIES OF SPEAKERS AND SESSION CHAIRS
mediator of Angiotensin II induced renal and vascular fibrosis (Am J Pathol 61...
BIOGRAPHIES OF SPEAKERS AND SESSION CHAIRS
Prof. Catherine Godson
University College Dublin, Dublin, Ireland
Catherin...
of 13

Presenter Bios

Published on: Mar 4, 2016
Source: www.slideshare.net


Transcripts - Presenter Bios

  • 1. BIOGRAPHIES OF SPEAKERS AND SESSION CHAIRS Prof. Peter Maxwell Queens University, Belfast, U.K Peter Maxwell is a consultant nephrologist in the Regional Nephrology and Transplant Unit, Belfast City Hospital and is Professor of Renal Medicine at Queens University Belfast. His research interests include genetic predisposition to renal disease and epidemiology of chronic kidney disease. a.p.maxwell@qub.ac.uk Prof. Per-Henrik Groop Folkhälsan Research Center, Helsinki, Finland Per-Henrik Groop, MD, DMSc, is a specialist in diabetes and nephrology. He is the Head of the Department of Diabetes Genetics at the Folkhälsan Research Center in Helsinki, Finland. He is also Deputy Chief Physician at the Helsinki University Central Hospital, Department of Medicine. His main work is focused on the dissection of the pathogenesis of diabetic complications with special emphasis on diabetic nephropathy. In 1997 he initiated the large, nation-wide, comprehensive Finnish Diabetic Nephropathy Study (the FinnDiane Study) that includes 5000 patients with type 1 diabetes and their family members recruited via a network of 92 hospitals and health care stations throughout Finland. The collection covers 16% of all patients with type 1 diabetes in Finland. He served as the associate editor of Diabetologia 2005-2007, and currently as associate editor of Kidney International and International Diabetes Monitor. He is the President of the European Diabetic Nephropathy Study Group (EDNSG). per-henrik.groop@helsinki.fi
  • 2. BIOGRAPHIES OF SPEAKERS AND SESSION CHAIRS Dr. Lise Tarnow Steno Diabetes Centre, Gentofte, Denmark Dr. Lise Tarnow graduated from the Medical Faculty of the University of Copenhagen in 1990 and completed her postgraduate medical training in 1991. From 1991-1993 she was a registrar in internal medicine. In 1993 Dr Tarnow was employed as a research fellow at the Steno Diabetes Center, Gentofte, Denmark in the Parving group. During these years a deep interest has evolved in pathogenetic components and cardiovascular risk factors of diabetic nephropathy. Her research activities have been focused on the genetic risk factors involved in initiation and progression of diabetic nephropathy and the accompanying cardiovascular complications. At the University of Copenhagen in 2001 Dr Tarnow wrote her doctorial thesis: ‘Diabetic nephropathy: Pathogenetic aspects and cardiovascular risk factors’. From 2000 until 2007 she has worked as a senior researcher in the group of Professor Hans-Henrik Parving. In 2003 she received a research grant from the Bagger-Sørensen Foundation. In 2006 she was given the Bernhard Rasmussen and wife Meta Rasmussens diabetes award. Since April 2007 Dr Tarnow has been working at head of the clinical research unit at Steno Diabetes Center. Dr Tarnow has published more than 100 peer reviewed papers and 9 reviews or book chapters. The results of her work have furthermore been communicated through free communications and invited presentations at international meetings. She has been an active member of the European Association for the Study of Diabetes (EASD) and the European Diabetic Nephropathy Study Group since 1993. Furthermore she holds a membership of the Danish Society of Endocrinology, Hypertension and Cardiology. ltar@steno.dk Dr. David Savage Queen’s University, Belfast, U.K David Savage graduated with a PhD in genetics from the University of Ulster. After a lengthy career as a bioscientist in molecular diagnostics in the NHS and a post doctoral fellowship at the IMCB, National University of Singapore, he was appointed lecturer in the Department of Medical Genetics, Queen’s University Belfast (QUB) in 1995. He is currently Reader in Molecular Medicine and academic lead for the Genomics Core Technology Unit at QUB. In 2008 he was appointed Visiting Assoc. Professor at University College Dublin (UCD). In collaboration with colleagues at
  • 3. BIOGRAPHIES OF SPEAKERS AND SESSION CHAIRS UCD, his research group is focussed on applying molecular based strategies to identify the genetic predisposition to diabetic nephropathy (DN) in type 1 diabetes. Furthermore, in collaboration with others he was instrumental in establishing the UK Warren 3 and GoKinD DNA & cell line collections for DN. His group has published extensively on candidate gene based association studies in DN employing a case control design. However, they have recently turned their attention to conducting Genome Wide Association Studies (GWAS), as well as investigating the role of DNA methylation and miRNAs in diabetic kidney disease. d.savage@qub.ac.uk Dr. Andrzej S. Krolewski Joslin Diabetes Centre, Harvard Medical School, Boston, USA Dr. Krolewski was trained as a physician and epidemiologist at the Warsaw Medical University, Warsaw, Poland. After coming to the U.S. and after completing fellowships in epidemiology at Harvard and molecular human genetics at MIT, he established a new research section at the Joslin Diabetes Center, the Section on Genetics and Epidemiology. Capitalizing on his access to the 15,000 patient population of the Joslin Clinic, he has established a population laboratory for studies of the epidemiology and genetics of diabetes and it late complications. Over the last 15 years his research focused on three areas. 1) Epidemiology of diabetic nephropathy in type 1 diabetes 2) Genetic susceptibility to diabetic nephropathy 3) Genetic susceptibility to type 2 diabetes Currently Dr. Krolewski is a Senior Investigator, Section Head on Genetic and Epidemiology at the Joslin Diabetes Center and Associate Professor of Medicine at Harvard Medical School, Boston. MA, USA. andrzej.krolewski@joslin.harvard.edu Prof. Finian Martin University College Dublin, Dublin, Ireland. Finian Martin, molecular cell biologist, is a Principal Investigator at the UCD Conway Institute, University College Dublin. His major research interest is in the intracellular signalling strategies that support the functional and structural
  • 4. BIOGRAPHIES OF SPEAKERS AND SESSION CHAIRS behaviour of epithelial cells. For the last 10 years he has contributed to the UCD DN group’s characterisation of novel gene products whose expression contributes to disease progression in diabetic nephropathy. He is currently contributing to the group’s programme to develop new strategies for modulating TGF-beta/BMP signalling. finian.martin@ucd.ie Dr. Mario Schiffer Hannover Medical School, Hannover, Germany Mario Schiffer graduated from Medical School at the Free University of Berlin in 1999. He did his residency at the University of Erlangen-Nuremberg. After that he worked as a research associate at the Albert Einstein College of Medicine, Bronx, New York with Erwin Böttinger, M.D. initially supported by the German Research Council (DFG), followed by Fellowship Awards by the Juvenile Diabetes Research Foundation and the National Kidney Foundation. He returned to Germany to Hannover Medical School in September 2004 and started his own research group. Mario’s research group focuses on signalling pathways involved in the initiation and progression of podocyte loss. Mario’s research team examines several cytokines and chemokines in the context of apoptosis induction and evaluates the cellular response with regard to initiation and execution of apoptosis as well as survival signalling pathways involved in neutralizing the proapoptotic response. The major research focus of his team is the extra- and intracellular modification of TGF-β and BMP-pathways in podocytes. In that context, his lab examines the role and regulation of the adaptor molecules CD2AP and CIN85 as well as Protein Kinase C (PKC). To elucidate the intracellular crosstalk Mario’s group has generated several deficient podocyte cell lines and podocyte specific knockout mouse models. His team has developed a zebrafish based high throughput assay system to evaluate the effect of gene knockdowns on glomerular slit diaphragm function. Dr. Schiffer’s lab has recently identified a sensitive balance of adaptor molecules influencing the intracellular signalling response. They are currently dissecting the effects of various PKC-isoforms on podocyte function and signalling response and found that PKCs play an important role in podocyte differentiation, apoptosis and stabilization of the glomerular filtration slit. Dr. Schiffer practices Nephrology at the Hannover Medical School. His laboratory is funded by the German Research Council and currently holds an Extended Emmy Noether Excellence Award. schiffer.mario@mh-hannover.de
  • 5. BIOGRAPHIES OF SPEAKERS AND SESSION CHAIRS Dr. Roel Goldschmeding University Medical Centre Utrecht, The Netherlands Goldschmeding is from Groningen in the Netherlands. After studying medicine and classical piano in Groningen, he pursued a PhD in Target Antigens of ANCA in Systemic Vasculitis. Over the years he has worked at the University of Amsterdam, CLB and AMC Amsterdam and has been Associate Professor of Pathology at UMCU, University Medical Centre Utrecht Specialising in Nephropathology, Immunopathology and Rheumatology since 1997. Dr. Goldschmeding has published extensively and has taken mini-sabbaticals to University of Erlangen-Nuremberg, Germany in 2004 and FibroGen Inc., South San Francisco, CA in 2007. r.goldschmeding@umcutrecht.nl Dr. Derek P. Brazil University College Dublin, Dublin, Ireland Derek Brazil is a native of Dublin city, Ireland and graduated with a first class honours degree in Pharmacology at University College Dublin in 1992. He carried out his PhD research in the laboratory of Prof. Peter Gierschik in the University of Ulm, Germany, and graduated in 1997. He then spent three years as a postdoctoral fellow in medicine at the Joslin Diabetes Centre, Harvard Medical School, Boston in the laboratory of Prof. Morris White. After working as a senior research fellow in the laboratory of Dr. Brian Hemmings at the Friedrich Miescher Institute, Basel, he returned to Ireland in 2003 to University College Dublin to establish his research group working on the molecular cell biology of diabetes and its related complications. Derek’s research has focussed on insulin signalling pathways in diabetes, with a particular emphasis on in vivo mouse models of disease. He has published widely on the role of proteins such as IRS-2 and PKB/Akt in neuronal survival, diabetes and cancer. His current research team of five PhD and MD researchers based in the UCD Conway Institute are working on in vitro and in vivo models of diabetic nephropathy, exploring the roles of molecules such as Gremlin, IRS-2 and PKB/Akt in disease onset and progression. His group is part of the recently established UCD Diabetes Research Centre based in the UCD Conway Institute. Derek.brazil@ucd.ie
  • 6. BIOGRAPHIES OF SPEAKERS AND SESSION CHAIRS Dr. Susan Quaggin Samuel Lunenfeld Research Institute, Toronto, Canada Susan Quaggin graduated from the Faculty of Medicine at the University of Toronto in 1988 and received her specialty degree in Internal Medicine in 1992. She completed her sub-specialty training in Nephrology in 1993 at U of T and did a post- doctoral fellowship at Yale University where she studied the genetic basis of kidney development. In 1997, she returned to Toronto to do a second post-doctoral fellowship in mouse genetics in the laboratory of Janet Rossant. Currently she is an Associate Professor in the Department of Medicine, an Investigator at the Samuel Lunenfeld Research Institute and is a practicing Nephrologist at St. Michael’s Hospital. Susan’s research program focuses on the genetic pathways required to establish and maintain the glomerular filtration barrier – a highly selective filter that separates the blood from the urinary space. To understand the pathways and interactions between different cell types in the glomerulus that are critical to set up the filtration barrier, Susan’s research team has developed a number of genetic tools that permit cell and time-specific manipulation of gene expression. Using these tools, her lab has shown that VEGF-A is a major angiogenic factor required in the glomerulus. ‘Tweaking’ the dose of VEGF-A within the glomerulus leads to distinct and dramatic glomerular phenotypes during development and in adult mice. These phenotypes resemble a variety of glomerular lesions from thrombotic microangiopathy, to focal segmental glomerulosclerosis, two major causes of renal disease in patients. Loss of all VEGF- A within the glomerulus results in a complete failure of the filtration barrier to form. Dr. Quaggin’s lab is currently dissecting the upstream and downstream effectors of the VEGF-A signaling pathway that include the transcription factor, Pod1, and the Von Hippel Lindau gene. Her research laboratory is funded by CIHR, the Kidney Foundation of Canada, and NCIC, and Dr. Quaggin holds a Canada Research Chair Tier II in vascular biology and a Premier’s Research of Excellence Award. quaggin@msirc.on.ca
  • 7. BIOGRAPHIES OF SPEAKERS AND SESSION CHAIRS Dr. Ruth Gimeno Cardiovascular and Metabolic Diseases, Wyeth Research Cambridge, Massachusetts, USA Ruth Gimeno completed her undergraduate work at the University of Wuerzburg, Germany, and received her Ph.D in Biology from the Massachusetts Institute of Technology in Cambridge, MA, USA. In 1996, she joined Millennium Pharmaceuticals, initially as a postdoctoral fellow working with Dr. Lou Tartaglia, and later as a staff scientist in the metabolic disease group focusing on the identification of novel targets for obesity and type 2 diabetes. During her time at Millennium Pharmaceuticals, Dr Gimeno identified and characterized UCP2, the second member of the uncoupling protein family. Working in close collaboration with Dr Lodish’s group at the Whiteheard Institute of Biomedical Research, Dr. Giemon’s group characterized the biological function of a family of fatty acid transport proteins. In 2003, Dr Gimeno joined Wyeth Research in Cambridge, MA, USA, where she currently heads the metabolic disease target identification group within the cardiovascular and metabolic disease department. Her work at Wyeth is focused on targets and pathways involved in the pathogenesis of type 2 diabetes and diabetic nephropathy. rgimeno@wyeth.com Prof. Mark E. Cooper Baker Heart Research Institute, Melbourne, Australia Dr Mark Cooper is the head of Danielle Alberti Memorial Centre for Diabetes Complications at the Baker Heart Research Institute. He is head of the Diabetes & Metabolism Division which encompasses not only diabetic complications but also laboratories studying metabolism and epigenetics. He holds honorary appointments as a Professor of Medicine at both Monash University and University of Melbourne. He is a trained endocrinologist with an appointment at the co-located Alfred Hospital. Dr Cooper studied medicine at the University of Melbourne and then completed his physician’s training at the Austin Hospital as well as his PhD under Dr George Jerums and Professor Austin Doyle in the University of Melbourne Department of Medicine, Austin Hospital. Dr Cooper has successfully competed for a large number of peer reviewed grants over the last 15 years from a range of organizations including not only JDRF but also the National Health & Medical Research Council of Australia, National Institutes of Health, National Heart
  • 8. BIOGRAPHIES OF SPEAKERS AND SESSION CHAIRS Foundation of Australia, Diabetes Australia and Kidney Health Australia. In 1999 Dr Cooper was awarded the Eric Susman prize from the Royal Australasian College of Physicians for his research in the field of renal and vascular complications of diabetes. In 2005 he was awarded the Australian Diabetes Society (ADS) Kellion Award for outstanding contribution to diabetes research in Australia. In 1999 he was awarded a Centre Grant from JDRF which was subsequently renewed in 2003. He is the Deputy Director of a 5 year Centre grant awarded to Professor Brownlee and senior members of his team are directly involved in this research program. Dr Cooper is currently Co-Chair of the JDRF Medical Science Review Committee (Complications Panel). He is regularly invited to international meetings and has over 400 peer reviewed publications. mark.cooper@baker.edu.au Prof. Harry Holthofer Dublin City University, Dublin, Ireland Harry Holthofer MD, PhD graduated from the University of Helsinki, Finland and was trained in clinical microbiology/immunology. Along with hospital-based positions in disciplines including e.g. internal medicine, pulmology, pediatrics and occupational health, his research has focused on the biology of the glomerular filtration barrier, particularly in congenital nephrotic syndrome (minimal change) and, in more recent years, the diabetic end organ complications causing proteinuria. For that, various approaches ranging from molecular and cell biology, biochemistry combined with in vitro and in vivo analytic platforms have revealed new integral molecules constituting the slit diaphragm. Also, novel tools of conditionally targeted mouse models exclusively to the podocytes were created, along with the present activities to establish useful biosensors to detect filtration barrier abnormalities. Prof Holthofer has held visiting positions at various places such as Medical University of South Carolina, Charleston, Albert Einstein College of Medicine, New York, Harvard Medical School, Universities of Bonn and Munich, Germany, Stanford University. He became Professor, Director of the Technomedicum Research Centre from 2001-2006 in Finland and moved to Ireland to take up the Chair of Bioanalytical Sciences At Dublin City University to become Director of the Center for Bioanalytical Sciences in September 2006. He has set up and served as coodinator on several EU funded programmes and participated in others. He is a founding member of the International Committee to
  • 9. BIOGRAPHIES OF SPEAKERS AND SESSION CHAIRS Standardise Proteomics Methods in Kidney Research and European Kidney Health Initiative and serves in the boards of several research organisations. harry.holthofer@dcu.ie Dr. Madeline Murphy University College Dublin, Dublin, Ireland Madeline Murphy carried out her PhD research in the laboratory of Dr Patrick Joyce in University College Dublin and graduated in 1993. She spent three years as a postdoctoral fellow in the National Diagnostics Centre, Galway in the laboratory of Prof. Frank Gannon and Prof Terry Smith. She joined the research group of Prof Hugh Brady, Professor Finian Martin and Prof Catherine Godson in 1997 working on the molecular cell biology of diabetic nephropathy. She currently directs her own research group as part of the recently established UCD Diabetes Research Centre based in the UCD Conway Institute Dr. Murphy’s research has focussed on differential gene expression in diabetic nephropathy. She has identified a number of genes that contribute towards disease development (i.e. CTGF, gremlin and IHG-1). Her research team consisting of one post-doctoral scientist and three graduate students currently investigate the contribution of gremlin and novel gene IHG-1 towards disease progression in diabetic nephropathy. Madeline.murphy@ucd.ie Prof. Herman Haller Hannover Medical School, Hannover, Germany Hermann Haller is presently Director of the Department of Nephrology at Hannover Medical School. He graduated from the Free University of Berlin in 1983. From 1983 until 1992 he trained at the Free University at Berlin and Yale Medical School. In 1992 he became Professor of Medicine at the Franz-Volhard-Clinic at the Max- Delbrück-Centre of Molecular Medicine in Berlin. Prof. Haller’s scientific interest is in hypertension, diabetic nephropathy and transplantation. He is especially interested in vascular complications and endothelial cell function in these areas. Prof. Haller is post-president of the German Hypertension Society. He has published more than 500 peer-reviewed articles. Prof. Haller has received the Folkow Award of the European Society of Hypertension, the Franz Volhard Prize of the German
  • 10. BIOGRAPHIES OF SPEAKERS AND SESSION CHAIRS Hypertension Society and the Jan Brod Award, Czech Society of Hypertension. He is also a principal investigator in international multicenter studies. haller.hermann@mh-hannover.de Dr. Denise Sadlier University College Dublin, Dublin, Ireland Denise Sadlier graduated from University College Dublin in 1996. She entered the Specialist Registrar Training programme in Nephrology & General Internal Medicine in 1999 and subsequently completed a Harvard Fellowship in Nephrology and Renal Transplantation working in both Brigham and Women’s Hospital and Massachusetts General Hospital in Boston, USA. In December 2005, Dr Sadlier was awarded a PhD for research into the molecular pathogenesis of renal fibrosis. She returned to Dublin as a Consultant Nephrologist and Senior Lecturer in Medicine at University College Dublin in 2007 where her areas of interest clinically include cardio-renal syndrome, electrolyte disorders and glomerular disease. In addition, she continues to pursue an active research programme in diabetic nephropathy and renal fibrosis. denise.sadlier@ucd.ie Dr. Valerie Clerin Wyeth Research Cambridge, Massachusetts, USA Valerie Clerin is Principal Research Scientist at Wyeth in Cambridge, MA, USA and leads the In Vivo Pharmacology effort in diabetic nephropathy within the Cardiovascular & Metabolic Diseases department. Over the past six years spent at Wyeth, Valerie has also been leading research programs for the development of new drug candidates for atherosclerosis and thrombosis. She graduated in Mechanical Engineering from Ecole Centrale in France and received her Ph.D. in Cardiovascular Bioengineering from University Paris12 in France, followed by 2-year postdoctoral fellowship in the Institute for Medicine and Engineering at the University of Pennsylvania in Philadelphia.
  • 11. BIOGRAPHIES OF SPEAKERS AND SESSION CHAIRS / Kumar Sharma University of California, San Diego, California, USA Kumar Sharma is a leading translational researcher whose major area of interest is diabetic complications and kidney disease. His studies have identified several key mediators of early and progressive kidney disease associated with diabetes and obesity. His landmark studies demonstrating the role of the growth factor, TGF-β, have led to the development of clinical applications using approaches to block TGF-β for human diabetic nephropathy. In addition, Dr. Sharma has been involved in his own anti-fibrotic approaches for patients with advanced diabetic nephropathy and recently completed an NIH-funded randomized clinical trial. Most recently, Dr. Sharma’s group has identified a key role for adiponectin to play a role in early proteinuria associated with obesity. His studies have been published in the JCI, PNAS, JBC, PlOS-Medicine, JCB, AJP-Renal, JASN and Kidney International. Dr. Sharma has recently joined UCSD to lead translational research in kidney disease. He has continuous NIH funding since 1996 and presently has several NIH grants, ADA and JDRF support for his research. kumarsharma@ucsd.edu Dr. Marta Ruiz Autonoma University of Madrid, Madrid, Spain Marta Ruiz-Ortega, PhD, is a Professor at the Department of Medicine in the Autonoma University of Madrid, Spain. She is the director of the laboratory of Cellular Biology in Renal Diseases and Hypertension at the Department of Nephrology in the Fundación Jimenez Diaz. She has been working in the field of Nephrology and Vascular Pathology for almost 15 years. Most of her work has been related to the actions of Angiotensin II, the main peptide of the renin angiotensin system. Her most important contribution has been to demonstrate that Angiotensin II is a true cytokine that participates in the inflammatory response through the regulation of the nuclear factor kappa B (Cir. Res. 86:1266-1272, 2000; Am. J. Pathol 158:1743-1756, 2001; Nephrol. Dial. Transplant. 16: 1-7, 2001; Current Opin Nephrol Hypertens 10:321-329, 2001.). One important line of her research is the investigation of the mechanisms involved in fibrosis. In this field, she showed that connective tissue growth factor is a
  • 12. BIOGRAPHIES OF SPEAKERS AND SESSION CHAIRS mediator of Angiotensin II induced renal and vascular fibrosis (Am J Pathol 613: 1937-1947, 2003; Circulation. 108: 1499-1509,2003). In the field of Nephrology, she is collaborating with Dr. Sergio Mezzano and Dr. Jesus Egido, they are investigating the molecular mechanisms involved in renal damage progression, trying to find novel targets for renal fibrosis as well as potential biomarkers. They have recently demonstrated that Angiotensin II, independently of TGF-β, activates the Smad pathway in the kidney (Kidney Int in press). marta.ruiz.ortega@uam.es Dr. Thomas M. Coffman Duke University City, North Carolina, USA Thomas Coffman is James R. Clapp Professor of Medicine and the Chief of the Division of Nephrology at Duke. Dr. Coffman graduated cum laude from the University of Pennsylvania and obtained his M.D. from the Ohio State University School of Medicine. He undertook his internal medicine and nephrology training at Duke. A national leader in the field of nephrology, Dr. Coffman has served on a number of NIH review panels and advisory boards, and serves on the editorial boards of the American Journal of Physiology, Physiological Reviews, and Cell Metabolism. He is also a member of the Nephrology Subspecialty Board of the American Board of Internal Medicine (ABIM), the American Society for Clinical Investigation and the Association of American Physicians. He is a councilor for the American Society of Nephrology and will serve as the Society’s President in 2009. Dr. Coffman is a Fellow of the American Heart Association Council for High Blood Pressure Research and its Kidney Council, and has served as Chair of the AHA Cardio-Renal Study Section. Dr. Coffman’s research interests include the pathogenesis and treatment of hypertension, diabetic nephropathy, and the renin- angiotensin system. His laboratory is supported by grants from the NIH and the Department of Veterans’ Affairs. Dr. Coffman has served as a scientific consultant for a number of companies including Merck, Pfizer, Lexicon Genetics, Tularik, Exilixis, and Ren Pharmaceuticals. tcoffman@acpub.duke.edu
  • 13. BIOGRAPHIES OF SPEAKERS AND SESSION CHAIRS Prof. Catherine Godson University College Dublin, Dublin, Ireland Catherine Godson is Professor of Molecular Medicine at University College Dublin and Director of UCD Diabetes Research Centre. She obtained her BSc (Biochemistry) and PhD (Pharmacology) from University College Dublin and, following postdoctoral fellowships in Geneva and at UC San Diego, joined the faculty of Harvard University. She moved to UCD in 1997. She leads a group of investigators focused on the molecular mechanisms underlying the initiation, progression and potential regression of diabetic kidney disease. This programme is supported by Science Foundation Ireland and involves major collaboration with the investigators in the biopharma industry. Professor Godson has an international reputation in research on inflammation and its resolution, microvascular complications of diabetes and extracellular signal transduction and has authored or co-authored over 100 research papers, review articles, patents and book chapters. Professor Godson’s research activities are supported by grants from Science Foundation Ireland, The Wellcome Trust, The Health Research Board and The European Union. She is a board member of the Health Research Board, a member of The European Medical Research Council, a member of the Wellcome Trust’s Physiological Sciences Committee and has recently completed a term as Vice President, Innovation and Corporate Partnerships at University College Dublin. catherine.godson@ucd.ie

Related Documents